List of Excipients in Branded Drug BUTENAFINE HYDROCHLORIDE

« Back to Dashboard

Generic Drugs Containing BUTENAFINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Albertsons	butenafine hydrochloride	21130-965	BENZYL ALCOHOL
Albertsons	butenafine hydrochloride	21130-965	CETETH-23
Albertsons	butenafine hydrochloride	21130-965	CETYL ALCOHOL

What are the Most Frequently-Used Excipients in BUTENAFINE HYDROCHLORIDE?

# Of NDCs	Excipient
5	BENZYL ALCOHOL
5	CETETH-23
5	CETYL ALCOHOL

Butenafine Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: October 7, 2026

Butenafine hydrochloride is a mature topical antifungal with limited active-ingredient exclusivity and broad formulation flexibility. The main commercial opportunities are differentiated creams, gels, sprays, foams, films, and low-irritancy formulations that improve patient adherence, cosmetic acceptability, application convenience, or treatment of difficult anatomical sites. The strongest development path is an OTC or authorized-generic product supported by formulation know-how rather than a new chemical-entity patent.

What is the regulatory and commercial status of butenafine hydrochloride?

Butenafine hydrochloride is a topical benzylamine antifungal marketed in the United States at a 1% concentration. Prescription products include Mentax cream, while OTC products include Lotrimin Ultra and store-brand equivalents. The drug is indicated for superficial fungal infections, including tinea pedis, tinea corporis, and tinea cruris, subject to product labeling.[1,2]

Attribute	Butenafine hydrochloride
Therapeutic class	Topical antifungal
Chemical form	Hydrochloride salt
Common strength	1%
Main dosage form	Topical cream
U.S. prescription product	Mentax
U.S. OTC product	Lotrimin Ultra and private-label equivalents
FDA pathway	NDA for prescription products; OTC monograph pathway for compliant products
Biosimilar relevance	None
Primary commercial issue	Differentiation in delivery, tolerability, convenience, and retail positioning
Primary patent issue	Mature active ingredient with limited practical composition-of-matter protection

The FDA OTC antifungal monograph permits specified active ingredients, concentrations, and labeling conditions for eligible products. Butenafine hydrochloride 1% is included among the permitted topical antifungal actives under the applicable FDA framework.[3] A compliant product can therefore compete without relying on a new drug approval, provided its formulation, labeling, manufacturing, and quality systems satisfy the monograph and applicable FDA requirements.

What excipients are used in marketed butenafine hydrochloride cream?

The reference-style cream formulation uses a conventional oil-in-water emulsion. Public labeling for Mentax identifies inactive ingredients including benzyl alcohol, cetyl alcohol, cetyl esters wax, isopropyl myristate, polysorbate 60, purified water, sodium hydroxide, and stearyl alcohol.[1]

Excipient	Probable formulation function	Commercial implication
Benzyl alcohol	Preservative; solvent; antimicrobial support	Can contribute to irritation or sensitization concerns in some users
Cetyl alcohol	Consistency agent; emollient; co-emulsifier	Supports cream structure and skin feel
Cetyl esters wax	Emollient; viscosity builder	Improves body and spread profile
Isopropyl myristate	Emollient; penetration and spread enhancer	Can improve slip but may affect occlusivity and irritation profile
Polysorbate 60	Nonionic emulsifier	Stabilizes the oil-in-water system
Purified water	Continuous phase	Controls viscosity, cooling, and application feel
Sodium hydroxide	pH adjustment	Controls active stability and preservative performance
Stearyl alcohol	Structuring agent; emollient; co-emulsifier	Increases viscosity and cream persistence

The formula is commercially efficient because it uses common excipients with established topical precedent. Its limitations are equally clear. It is a conventional cream, includes benzyl alcohol, depends on a wax-alcohol structure, and may leave room for improvements in drying time, residue, odor, spreadability, and use on hairy or intertriginous areas.

How should an excipient strategy be designed for butenafine hydrochloride?

A development program should begin with the active’s physicochemical profile and the target anatomical site. Butenafine hydrochloride is a lipophilic topical antifungal salt. The formulation must maintain drug uniformity, preserve chemical stability, support release from the vehicle, and keep the product acceptable during repeated application.

Target product profile

A commercially competitive product should aim for:

• 1% butenafine hydrochloride unless a different strength has a clear regulatory basis.
• Uniform drug distribution throughout shelf life.
• Rapid application and short rub-in time.
• Low tack and limited residue.
• Minimal odor.
• Appropriate preservation without avoidable sensitizers.
• Stable viscosity across temperature excursions.
• Packaging that limits water loss and contamination.
• Demonstrated in vitro release and, where necessary, comparative clinical performance.

The excipient choice should follow the intended product category. A cream designed for interdigital tinea pedis has different requirements from a spray intended for broad-area use or a gel intended for hairy skin.

Cream strategy

The lowest-risk path is a reformulated cream using the current excipient architecture. Opportunities include:

• Replacing or reducing benzyl alcohol if preservation and stability permit.
• Optimizing fatty alcohol ratios to reduce waxiness.
• Adjusting the emollient phase to improve spread and reduce greasiness.
• Using a modern nonionic emulsifier system with improved sensory performance.
• Controlling pH to balance drug stability, skin tolerability, and preservative activity.
• Reducing residual film while preserving residence time.

A “sensitive skin” positioning would require careful support. Removing benzyl alcohol may improve the tolerability narrative, but preservation must be demonstrated through antimicrobial effectiveness testing and stability studies. Preservative substitution is not automatically superior. Phenoxyethanol, organic acids, parabens, and multifunctional excipients each create different regulatory, compatibility, and consumer-perception considerations.

Gel strategy

A hydroalcoholic or aqueous gel could target patients who prefer a lighter vehicle. Potential advantages include rapid drying, lower residue, and improved use on hairy or plantar areas. The principal technical risks are:

• Incomplete drug solubilization or crystallization during storage.
• Greater sting on fissured or inflamed skin.
• Alcohol-related dryness.
• Lower residence time after application.
• Packaging compatibility with volatile solvents.
• Potentially different in vitro release behavior from the cream.

A nonalcoholic emulsion-gel could reduce sting and dryness while retaining a lighter texture. Carbomer, cellulose derivatives, poloxamers, or associative rheology modifiers may be considered, but each can alter release, pH, viscosity, and preservative performance.

Spray and foam strategy

A spray or foam offers the clearest convenience differentiation. These dosage forms may be attractive for:

• Broad-area tinea corporis.
• Hair-bearing skin.
• Patients who avoid touching infected areas.
• Sports, travel, and on-the-go use.
• Retail products positioned around cleanliness and convenience.

The product must control dose uniformity per actuation. Spray systems can generate variable delivery depending on orientation, priming, distance, and remaining container volume. Foams add complexity in propellant selection, valve performance, flammability, package integrity, and drug distribution.

A pump spray without volatile organic propellant may have a more favorable regulatory and sustainability profile than an aerosol. Its commercial weakness is potentially lower sensory appeal and less efficient coverage of large areas.

Film-forming strategy

A film-forming solution or gel could provide extended residence time and reduce application frequency. Film-formers such as acrylate polymers, polyvinylpyrrolidone-based systems, or cellulose derivatives can create a durable layer after solvent evaporation. The design risks include cracking, whitening, transfer to clothing, discomfort, and impaired patient acceptance.

A film-forming claim should not be treated as a substitute for clinical evidence. Longer residence on the skin does not establish improved cure rates. The development program should compare mycological and clinical outcomes against an appropriate marketed comparator.

What formulations are protected by butenafine hydrochloride patents?

The practical protection for a new butenafine product is more likely to come from formulation, device, manufacturing, or use claims than from the active ingredient itself. Butenafine has been commercially available for many years, and the basic 1% cream concept is mature.

Potential claim categories include:

Claim category	Potential protection
Composition	Specific excipient ratios, pH, rheology, particle size, or solvent system
Dosage form	Foam, spray, film-forming gel, emulsion-gel, or anhydrous system
Device	Metered-dose delivery, applicator, valve, or package configuration
Manufacturing	Mixing sequence, temperature profile, homogenization, deaeration, or crystallization control
Stability	Reduced degradation, lower impurity formation, or improved preservative robustness
Method of use	Shorter treatment duration, less frequent dosing, or defined anatomical use
Packaging	Airless pump, unit-dose sachet, contamination-resistant tube, or multilayer package

Formulation claims are strongest when tied to measurable technical results, such as improved stability, controlled release, reduced crystallization, improved dose uniformity, or clinically meaningful tolerability. Broad claims covering a conventional cream with routine excipient substitutions are vulnerable to obviousness challenges.

How many patents cover butenafine hydrochloride?

The relevant patent count depends on the jurisdiction, family consolidation, prosecution status, and whether expired patents are included. A raw patent count is not a reliable measure of current exclusivity.

For U.S. commercial planning, the critical distinction is between:

1. Expired or abandoned foundational patents.
2. Active formulation or delivery patents.
3. Orange Book-listed patents associated with an approved prescription product.
4. Non-listed patents that may still be asserted in commercial disputes.
5. Pending applications with uncertain enforceability.

The original active-ingredient and early formulation rights are unlikely to create a meaningful barrier to a compliant 1% OTC product. The current competitive barrier is more likely to be brand recognition, retail distribution, regulatory execution, formulation performance, and manufacturing cost.

What is the Orange Book status of butenafine hydrochloride?

The Orange Book is relevant primarily to approved prescription products, including Mentax. It is not the central exclusivity database for OTC monograph products. OTC products marketed under the monograph system generally do not receive the same Orange Book patent-listing role as NDA products.[4]

The commercial implications are:

• An OTC monograph competitor does not normally need to resolve an Orange Book Paragraph IV challenge to launch a compliant product.
• A prescription applicant relying on an NDA pathway may face product-specific patent and exclusivity issues.
• Orange Book listing status must be evaluated for the specific NDA and current product record, not inferred from the active ingredient.
• OTC monograph status can reduce regulatory cost but does not eliminate formulation, labeling, cGMP, or quality obligations.

When does butenafine hydrochloride lose exclusivity?

The active ingredient has already passed the period in which new chemical entity exclusivity would control ordinary competition. Any remaining commercial protection depends on product-specific patents, regulatory exclusivity, trademarks, and formulation differentiation.

For a new OTC monograph product, the relevant launch question is usually not “when does the active ingredient lose exclusivity?” It is whether the proposed product complies with the current monograph and whether it avoids protected formulation or brand assets. A generic or store-brand cream can compete on price, but it must still demonstrate identity, strength, purity, quality, stability, and manufacturing control.

Are there Paragraph IV challenges for butenafine hydrochloride?

Paragraph IV litigation is generally associated with abbreviated new drug applications that challenge listed patents for an NDA product. The risk is limited where the commercial product is launched under the OTC monograph pathway rather than through an ANDA referencing a patented NDA product.

For butenafine, a Paragraph IV strategy would be relevant if:

• A prescription NDA has current, listed patents.
• The applicant seeks approval through an ANDA.
• The listed patent claims cover the referenced product or approved use.
• The applicant submits a certification challenging validity, enforceability, or infringement.

A monograph-compliant OTC launch follows a different regulatory route. It may avoid the Orange Book patent-certification process, although it remains exposed to ordinary patent litigation involving formulation, device, trade dress, or manufacturing rights.

What generic launch risks exist for butenafine hydrochloride?

The generic launch risk is high for a conventional 1% cream because the active ingredient is mature and the reference formulation uses standard topical excipients. The main risks are executional.

Technical risks

• Drug crystallization during storage.
• Poor content uniformity in a semisolid batch.
• Inadequate preservative performance.
• Phase separation or viscosity drift.
• Inconsistent release from batch to batch.
• Tube or pump incompatibility.
• Microbial contamination during use.

Regulatory risks

• Misclassification of the product under the OTC framework.
• Labeling that exceeds permitted monograph claims.
• Unsupported claims involving faster cure, superior efficacy, or reduced dosing.
• Inadequate stability data.
• Failure to control impurities or extractables and leachables.
• Deficiencies in topical product manufacturing controls.

Commercial risks

• Strong price competition from private-label products.
• Low consumer recognition outside established brands.
• Limited willingness to pay for an undifferentiated cream.
• Retail substitution by terbinafine, clotrimazole, or miconazole products.
• Seasonal demand concentration.
• High customer-acquisition costs for a new consumer brand.

How does butenafine compare with terbinafine and azole antifungals?

Butenafine competes in a crowded OTC antifungal market. Terbinafine has strong consumer recognition and is often marketed around short treatment courses. Clotrimazole and miconazole have broad brand and private-label penetration. The commercial advantage of butenafine is not a unique market category; it is the opportunity to pair a familiar 1% active with a better product experience.

Product class	Typical differentiation	Main threat to butenafine
Butenafine	Established benzylamine; cream and OTC availability	Lower brand visibility
Terbinafine	Short-course positioning; strong retail recognition	Treatment-duration advantage
Clotrimazole	Broad historical use; extensive private label	Low price and shelf presence
Miconazole	Brand familiarity and multiple dosage forms	Strong consumer awareness
Tolnaftate	Low-cost legacy antifungal	Price competition

A butenafine product should avoid competing only on active ingredient. A better strategy is to select a defined use case, such as non-greasy foot treatment, spray delivery for hard-to-reach areas, or a low-odor formulation for daily use.

What manufacturing and intellectual-property barriers matter?

Manufacturing barriers are moderate for a conventional cream and higher for sprays, foams, films, and advanced emulsion systems.

A standard cream requires validated control of:

• Raw-material identity and microbiological quality.
• Active dispersion and uniformity.
• Emulsion formation.
• Homogenization.
• Cooling and wax crystallization.
• Bulk hold time.
• Filling accuracy.
• Microbial limits.
• Preservative effectiveness.
• Stability under accelerated and long-term conditions.

Advanced products add device and package controls. A foam may require specialized filling equipment. A spray requires actuation testing and delivery-performance studies. A film-forming product may require solvent-loss controls and specialized container closure systems.

The most defensible IP position usually combines composition claims with process and device claims. A single broad excipient patent is less durable than a portfolio covering the formulation, manufacturing process, applicator, package, and defined performance characteristics.

Which licensing deals and partnerships are commercially relevant?

The most realistic licensing opportunities are not licenses to the butenafine molecule. They are partnerships involving:

• OTC brand acquisition or private-label supply.
• Contract manufacture of topical semisolids.
• Proprietary spray, foam, or film-forming platforms.
• Airless and metered-dose packaging.
• Preservative-free or low-preservative technology.
• Retail distribution through pharmacies, mass merchants, and e-commerce.
• Regional rights for branded or generic products.

A licensee should value formulation and delivery know-how only if it reduces development time, improves stability, supports a defensible claim set, or solves a manufacturing problem. A basic cream formula using widely available excipients is unlikely to command substantial royalty economics unless paired with brand assets or established distribution.

What revenue exposure and commercial scenarios apply?

Butenafine revenue is exposed to substitution by other OTC antifungals and to private-label pricing. The product is suitable for several commercial models:

Scenario	Product	Investment level	Margin potential
Low-risk entry	Monograph-compliant 1% cream	Low	Low to moderate
Retail differentiation	Low-residue or sensitive-skin cream	Moderate	Moderate
Convenience platform	Pump spray or foam	Moderate to high	Moderate to high
Premium niche	Film-forming or extended-residence product	High	High if clinically supported
B2B opportunity	Private-label supply	Moderate	Moderate, volume dependent
Regional licensing	Brand or formulation rights	Variable	Dependent on territory and channel

The lowest-risk product is a conventional 1% cream. The highest potential value is in a delivery system that creates a real consumer benefit while remaining within a manageable regulatory pathway. Premium pricing requires evidence of better usability, not merely a longer excipient list.

What is the litigation and settlement outlook?

There is no inherent biosimilar litigation pathway for butenafine hydrochloride because it is a small-molecule topical drug, not a biologic. Litigation risk is more likely to involve:

• Patent infringement claims over a new formulation or delivery device.
• Trademark disputes involving OTC branding.
• Trade dress and packaging claims.
• ANDA litigation if a prescription NDA has relevant listed patents.
• False advertising claims based on unsupported superiority or treatment-duration statements.

Settlement value is likely to be limited for an ordinary monograph-compliant cream. A settlement becomes more commercially relevant when a branded product has a valuable formulation patent, a high-volume retail franchise, or a launch-threatening device patent.

Key Takeaways

• Butenafine hydrochloride is a mature 1% topical antifungal with limited active-ingredient exclusivity.
• The standard cream uses benzyl alcohol, fatty alcohols, cetyl esters wax, isopropyl myristate, polysorbate 60, water, and sodium hydroxide.
• The best excipient opportunities involve sensory improvement, preservation strategy, stability, and anatomical-site optimization.
• Cream reformulation is the lowest-risk path; sprays, foams, and films offer greater differentiation but higher technical and regulatory complexity.
• OTC monograph competition can avoid much of the Orange Book and Paragraph IV pathway.
• Patent value is most likely to arise from formulation, device, manufacturing, packaging, or defined-use claims.
• There is no biosimilar opportunity because butenafine is a small-molecule drug.
• Commercial success depends more on formulation performance, retail access, brand positioning, and manufacturing cost than on the active ingredient.
• A premium product requires measurable usability or adherence benefits supported by stability and clinical data.

FAQs

Can butenafine hydrochloride be formulated without benzyl alcohol?

Yes. A benzyl-alcohol-free formulation is technically feasible, but it requires a replacement preservation strategy, antimicrobial effectiveness testing, stability testing, and compatibility assessment. Removing benzyl alcohol alone does not establish a superior safety or tolerability profile.

Is a butenafine hydrochloride spray likely to be more valuable than a cream?

A spray can command greater differentiation because it improves convenience and reduces direct hand contact. Its value depends on dose uniformity, coverage, package performance, and consumer acceptance. The development burden is higher than for a conventional cream.

Can a new butenafine formulation receive patent protection?

Yes. Patent protection may be available for a novel composition, delivery system, manufacturing process, device, packaging configuration, or method of use. Routine substitution of one conventional excipient for another is less likely to support durable patent claims.

Is butenafine hydrochloride suitable for a private-label OTC product?

Yes. A compliant 1% OTC product can be developed for private-label distribution, subject to the applicable FDA monograph, labeling, cGMP, quality, stability, and manufacturing requirements. The primary commercial challenge is price competition.

Which excipient strategy best supports a premium butenafine product?

A low-residue, low-odor, rapidly spreading emulsion-gel or metered spray is more commercially defensible than a conventional cream with minor excipient changes. The formulation should target a specific consumer problem and generate measurable evidence of improved usability.

References

1. DailyMed. (n.d.). Mentax: Butenafine hydrochloride cream, 1% prescribing information. U.S. National Library of Medicine.
2. DailyMed. (n.d.). Lotrimin Ultra: Butenafine hydrochloride cream, 1% drug facts. U.S. National Library of Medicine.
3. U.S. Food and Drug Administration. (2022). Topical antifungal drug products for over-the-counter human use, 21 C.F.R. Part 333, Subpart C.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.